1- MSc in Biochemistry, Razi Vaccine and Serum Research Institute, Karaj, Iran , zshahramyar@gmail.com 2- Associated Professor of Venomous Animals and Antivenin Production Department, Razi Vaccine and Serum Research Institute, Karaj, Iran 3- MSc in Vaccine and Serum, Quality Control Department, Razi Vaccine and Serum Research Institute, Karaj, Iran
Abstract: (23322 Views)
Background: Our previous studies revealed an inhibitory effect of ICD-85 a venom derived peptide has been extracted by researchers of Razi vaccine and serum research institute, on breast cancer cell line (MDA-MB231). The present study was undertaken to evaluate the anti proliferative effect of HL60 cells.
Materials and methods: The effect of ICD-85 on proliferation of HL-60 cancer cells was determined using the MTT assay. A quantitative cytotoxicity assay based on the release of lactate dehydrogenase (LDH EC 1.1.1.27) was performed 24 h after exposure to various concentrations of ICD-85. The morphological changes of ICD-85 treated HL-60 cancer cells were observed under electron microscope.
Results: ICD-85 induced marked concentration inhibition of cancer cell proliferation with an IC50 value of 0.04µg/ml following 24 h incubation. Electron microscopic findings of ICD-85 treated cells showed nuclear material condensation, endoplasmic reticulum dilation, mitochondria swelling or degradation, increased cytoplasmic vacuoles, reduction or disappearance in cytoplasmic process and decreased nuclear/cytoplasmic ratio. LDH determination of cultured media of HL60 cells exposed to various concentration of ICD-85 revealed no significant changes in LDH levels compared with untreated cells.
Conclusion: The results of present study indicated that ICD-85 inhibited the cancer cell proliferation by inducing apoptosis rather than necrosis.
Shahramyar Z, Zare Mirakabadi A, Morovati H. Cytotoxicity effect of ICD-85 (Venom – derived peptides) on promyelocytic cancer cell lines (HL-60). MEDICAL SCIENCES 2012; 21 (4) :238-243 URL: http://tmuj.iautmu.ac.ir/article-1-521-en.html